| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $14.00 | Overweight | Cantor Fitzgerald |
| 7/11/2024 | $18.00 → $12.00 | Buy | Lake Street |
| 5/1/2024 | $30.00 → $23.00 | Buy | Craig Hallum |
| 5/1/2024 | Outperform → Mkt Perform | William Blair | |
| 5/1/2024 | $36.00 → $13.00 | Overweight → Neutral | JP Morgan |
| 1/31/2023 | $20.00 | Buy | Lake Street |
| 7/18/2022 | $15.00 | Buy | Craig Hallum |
| 7/26/2021 | Outperform | William Blair | |
| 7/26/2021 | $30.00 | Buy | Canaccord Genuity |
| 7/26/2021 | $24.00 | Overweight | JP Morgan |
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of h
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximately $45,000 will continue in 2025, as published in the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. This follows the recent announcement that the American Medical Association CPT® Editorial Panel approved the application to transition Barostim from Category III to Category I CPT codes, expected to be implemented on January 1, 2026. Additi
MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2024. Recent Highlights Total revenue for the third quarter 2024 was $13.4 million, an increase of 27% over the prior year quarterU.S. Heart Failure (HF) revenue for the third quarter of 2024 was $12.2 million, an increase of 30% over the prior year quarterActive implanting centers in the U.S. were 208, an increase of 31% over the prior year quarterFinal I
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy ("Barostim") to treat the symptoms of heart failure. In response to the increased utilization of Barostim therapy and the strong evidence supporting its clinical outcomes, the AMA CPT Editorial Panel accepted the application for Category I CPT codes. This decision will help further facilitate reimbursement for healthcare providers performing the Barostim procedure and enable broa
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to th
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart failure patients with reduced ejection fraction MINNEAPOLIS, Sept. 12, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the publication of new data in the Journal of the American College of Cardiology: Heart Failure. The data detail the durable improvements out to 24-months in the individual components of the Minnesota Living with Heart Failure (MLWHF) and EuroQual-5D (EQ-5D) quality of life measures. The publication builds on the data from the BeAT-HF trial (NCT02627196) published in 2024 in the E
MINNEAPOLIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointments of Kevin Ballinger and Mitch Hill to its Board of Directors, effective immediately. The Company also announced that long-serving board member Ali Behbahani will be leaving the board. Following these changes, the Company's Board of Directors consists of seven members. "We are thrilled to welcome Kevin and Mitch to our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "Their extensive experience in the medical device industry, coupled with their strong track records driving growth and innovation, will be invaluable a
MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for the inpatient setting as part of the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule. In FY 2024, Barostim was assigned to MS-DRGs 252, 253, 254 with a national average payment range of $17,000-$23,000. For FY 2025, Barostim will be reassigned to MS-DRG 276, which carries a national average payment of approximately $43,000. The new payment takes effect Oct. 1, 2024. "We applaud CMS' consideration and
MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 12:30 PM Eastern Time the same day via webcast.A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com.About CVRx, Inc.CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of hea
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. Recent Highlights Total revenue for the second quarter 2024 was $11.8 million, an increase of 24% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2024 was $10.5 million, an increase of 27% over the prior year quarterActive implanting centers in the U.S. were 189, an increase of 35% over the second quarter of 2023
SC 13D/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13D/A - CVRx, Inc. (0001235912) (Subject)
SC 13D/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G - CVRx, Inc. (0001235912) (Subject)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
3 - CVRx, Inc. (0001235912) (Issuer)
3 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
144 - CVRx, Inc. (0001235912) (Subject)
144 - CVRx, Inc. (0001235912) (Subject)
8-K - CVRx, Inc. (0001235912) (Filer)
10-Q - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
10-Q - CVRx, Inc. (0001235912) (Filer)
8-K - CVRx, Inc. (0001235912) (Filer)
144 - CVRx, Inc. (0001235912) (Subject)
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and
Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe
MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b
Craig-Hallum analyst Alexander Nowak maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $23 to $15.
CVRx (NASDAQ:CVRX) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 1 1 0 0 Analysts have recently evaluated CVRx and provided 12-month price targets. The average target is $15.83, accompanied by a high estimate of $23.00 and a low estimate of $12.00. Experiencing a 48.39% decline, the current averag
Lake Street analyst Frank Takkinen maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $18 to $12.
Gainers ASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDAQ:BIOR) shares rose 11.64% to $0.75. The company's market cap stands at $26.9 million. Qualigen Therapeutics (NASDAQ:QLGN) shares increased by 10.99% to $0.19. The market value of their outstanding shares is at $1.2 million. CVRx (NASDAQ:CVRX) stock moved upwards by 9.48% to $12.0. The company's market cap stands at $259.1 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 8.68% to $0.27. Fresh2 Group (NASDAQ:FRES) shares rose 7.56% to $0.34. The market value
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwards by 23.91% to $5.76. The company's market cap stands at $231.2 million. Bright Green (NASDAQ:BGXX) shares rose 23.07% to $0.36. The company's market cap stands at $69.0 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.42% to $5.65. The company's market cap stands at $76.8 million. Kineta (NASDAQ:KA) shares moved upwards by 22.11% to $0.53. The market value of their outstanding shares is at $6.4 million. CVRx (NASDAQ:CVRX) stock moved upwards by 21.57% to $7.89. The marke
Lake Street analyst Frank Takkinen maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $35 to $18.
Canaccord Genuity analyst William Plovanic maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $32 to $14.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 200 points on Wednesday. The Federal Reserve opted to keep the federal funds rate unchanged at 5.25% to 5.5%, as widely expected. The Dow traded up 0.55% to 38,022.21 while the NASDAQ rose 0.19% to 15,687.08. The S&P 500 also rose, gaining, 0.08% to 5,039.51. Check This Out: This Analyst With 86% Accuracy Rate Sees More Than 24% Upside In Lattice Semiconductor – Here Are 5 Stock Picks For April From Wall Street’s Most Accurate Analysts Leading and Lagging SectorsUtilities shares rose by 1.2% on Wednesday. In trading on Wednesday, energy shares fell by 1.6%. Top Headline Pfizer Inc. (N
Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00
Lake Street reiterated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $12.00 from $18.00 previously
Craig Hallum resumed coverage of CVRx, Inc. with a rating of Buy and set a new price target of $23.00 from $30.00 previously
JP Morgan downgraded CVRx, Inc. from Overweight to Neutral and set a new price target of $13.00 from $36.00 previously
William Blair downgraded CVRx, Inc. from Outperform to Mkt Perform
Lake Street initiated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $20.00
Craig Hallum initiated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $15.00
William Blair initiated coverage of CVRx, Inc. with a rating of Outperform
Canaccord Genuity initiated coverage of CVRx with a rating of Buy and set a new price target of $30.00
JP Morgan initiated coverage of CVRx with a rating of Overweight and set a new price target of $24.00
MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2024. Recent Highlights Total revenue for the third quarter 2024 was $13.4 million, an increase of 27% over the prior year quarterU.S. Heart Failure (HF) revenue for the third quarter of 2024 was $12.2 million, an increase of 30% over the prior year quarterActive implanting centers in the U.S. were 208, an increase of 31% over the prior year quarterFinal I
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to th
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. Recent Highlights Total revenue for the second quarter 2024 was $11.8 million, an increase of 24% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2024 was $10.5 million, an increase of 27% over the prior year quarterActive implanting centers in the U.S. were 189, an increase of 35% over the second quarter of 2023
MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release second quarter 2024 financial and operating results after market close on Monday, July 29th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights Total revenue for the first quarter 2024 was $10.8 million, an increase of 35% over the prior year quarterU.S. Heart Failure (HF) revenue for the first quarter of 2024 was $9.7 million, an increase of 43% over the prior year quarterActive implanting centers in the U.S. grew to 190, an increase of 56% over the first quarter of 2023K
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its results at 5:00pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to t
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2023, and affirmed its 2024 business outlook. Recent Highlights Total revenue for the fourth quarter of 2023 was $11.3 million, an increase of 58% over the prior year quarterU.S. Heart Failure (HF) revenue for the fourth quarter of 2023 was $10.2 million compared to $6.0 million in the prior year quarter, an increase of 70% over the prior year quarterTota
MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To list
MINNEAPOLIS, Oct. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2023. Recent Highlights Total revenue for the third quarter of 2023 was $10.5 million, an increase of 70% over the prior year quarterU.S. Heart Failure (HF) revenue for the third quarter of 2023 was $9.4 million, an increase of 92% over the prior year quarterActive implanting centers in the U.S. grew to 159, an increase of 75% since September 30, 2022C
MINNEAPOLIS, Oct. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2023 financial and operating results after market close on Thursday, October 26th, 2023. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen